Objective: Polymorphisms in the apolipoprotein B (apoB) gene have been reported to be associated with coronary heart disease (CHD). However, the results on this topic are conflicting. The present study aims to derive a more precise estimation of the relationship between CHD and apoB genetic polymorphisms by meta-analysis. Methods: We identified a total of 54 studies involving 7236, 10,912, and 14,102 individuals, respectively, for EcoRI, XbaI, and SpIns/Del polymorphisms by searching in PubMed, Web of Science, Google Scholar, the Cochrane Library, Wanfang Data, SinoMed, and CNKI. We utilized RevMan 5.0 software to perform the meta-analyses. Results: A significant statistical association between apoB EcoRI polymorphism and CHD was observed under an allelic (p = 0.001, odds ratio (OR) = 1.33, 95% confidence interval (CI) = 1.12-1.57), dominant (p = 0.005, OR = 1.22, 95% CI = 1.06-1.40), and recessive (p = 0.04, OR = 1.33, 95% CI = 1.01-1.74) model. We also found similar association of apoB SpIns/Del polymorphism with CHD. However, we did not find association between apoB XbaI polymorphism and CHD. Conclusion: The current meta-analysis found an association of EcoRI polymorphism and SpIns/Del polymorphism with an increased risk of CHD. No significant association between apoB XbaI polymorphism and CHD we observed in the present study.
Introduction
Coronary heart disease (CHD) is one of the leading causes of death worldwide. Many studies have revealed that the interaction between various environmental factors and certain genetic polymorphisms may lead to CHD. Dyslipidemia have been documented as risk factors for CHD. Apolipoprotein B (apoB) is the sole protein component of low-density lipoprotein (LDL) which plays an important role in atherogenesis. The relationship between CHD and apoB gene polymorphisms has been a hotspot in recent years. The apoB gene is located on chromosome 2 and comprises 29 exons. 1 Numerous studies have focused on the correlation between the apoB gene polymorphism and CHD risk. However, these studies result in conflicting conclusions. Previous meta-analyses exploring the association between the apoB polymorphisms and CHD risk were also contradictory. Chiodini et al. found no evidence of increased risk emerged for XbaI polymorphism, 2 but positive associations were detected for EcoRI and SpIns/Del polymorphisms in CHD patients. Boekholdt et al. found that 
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homozygotes for the XbaI C allele had significantly elevated levels of LDL cholesterol (LDL-C) and apoB, 3 but a decreased risk of CHD in Caucasian populations. Homozygosity for the SpIns/Del D allele was associated with similarly increased levels of LDL-C and apoB, and with an increased risk of CHD. Homozygous subjects for the rare EcoRI allele had significantly decreased levels of total and LDL cholesterol. Chen et al. performed a study by collecting and sorting the previously published studies in Chinese individuals, 4 providing evidence that EcoRI A allele and XbaI C allele polymorphisms were a risk factor for the development of CHD, respectively .
To derive a more precise estimation of the relationship between CHD and these polymorphisms, we conducted a meta-analysis between the three most frequently investigated polymorphisms (XbaI, EcoRI, and SpIns/Del) of all published studies from 1990 to 2013.
Materials and methods

Literature search
All studies that reported the association between the apoB polymorphisms and CHD were identified by comprehensive computer-based searches of PubMed, Web of Science, Google Scholar, the Cochrane Library, Wanfang Data, China Biological Medicine Database(SinoMed), and China National Knowledge Infrastructure (CNKI). These computer searches were limited to English and Chinese language articles before March 2014, but did not include reviews and editorials. The following keywords were used for searching: "apolipoprotein B" OR "apoB" AND "polymorphism" OR "mutation" OR "variant" OR "variation" OR "genotype" AND "coronary heart disease" OR "CHD" OR "coronary artery disease" OR "CAD" OR "myocardial Infarction" OR "MI" OR "ischemic cardiovascular disease" OR "ischemic heart disease" OR "IHD".
Inclusion criteria
The diagnosis of CHD was fitted to the examination results of coronary arteriography, clinical symptoms combined with electrocardiogram, treadmill exercise test, echocardiography, and myocardial perfusion imaging in emission computed tomography. The inclusion criteria for identified articles were as follows: (1) studies are limited to three polymorphisms (XbaI, EcoRI, and SpIns/Del) of the apoB gene and CHD; (2) independent case-control studies using either a hospital-based or a population-based design; (3) similar to the literature research methods; (4) the literature has a comprehensive statistical index, sufficient data for estimating an odds ratio (OR) with 95% confidence interval (CI); (5) not republished data. Exclusion criteria were: (1) studies in which it was not possible to extract data from the published results; (2) studies that did not report appropriate outcomes were also excluded.
Data extraction
Two authors independently extracted data. Disagreement was resolved by consensus. If these two authors could not reach a consensus, the result was reviewed by a third author. The extracted data were consisted of the follow items: the first author's name, publication year, eligible subjects, number of genotypes, allele frequency of case, population, selection criteria, sex, and age of cases and controls.
Quality assessment
To determine the methodological quality of each study, we used the Newcastle-Ottawa scale, which uses a "star" rating system to judge the quality of observational studies. 5 The NOS ranges between zero (worst) up to nine stars (best). Studies with a score equal to or higher than seven were considered to be of high quality. Two investigators independently assessed the quality of included studies, and the result was reviewed by a third investigator. Disagreement was resolved by discussion.
Statistical analysis
The associations between XbaI, EcoRI, and SpIns/Del polymorphisms of apoB gene and CHD were compared by using the OR corresponding to 95% CI. Heterogeneity between studies was assessed by I 2 test, p < 0.10 and I 2 > 50% indicated evidence of heterogeneity. 6, 7 If heterogeneity existed among the studies, the random effects model was used to estimate the pooled OR (the DerSimonian and Kacker method). 8 Otherwise, the fixed effects model was adopted (the Mantel-Haenszel method). 9 For the apoB gene polymorphisms, we investigated associations between the genetic variant and CHD risk in a recessive dominant genetic model and allelic contrast. Z test was used to determine the pooled OR and significance was set at p < 0.05. Hardy-Weinberg equilibrium (HWE) for each single nucleotide polymorphism was assessed for the controls in each study using χ2 test at a significant level of p < 0.05. The potential publication bias was investigated by using funnel plots and Egger's test. 10 The statistical analysis was conducted by using Review Manager 5.20 (Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen). In order to observe the association between numerous polymorphic sites of apoB gene polymorphisms and CHD risk in Chinese, studies of Chinese were considered in the meta-analysis independently.
Results
Study characteristics
All of the studies had been approved by the ethics committees of their affiliations. A total of 54 studies were included in the final meta-analysis according to the inclusion criteria, 29 for EcoRI, 41 for XbaI, and 27 about SpIns/Del polymorphisms. Table1 shows the studies identified and their main characteristics. Figure 1 shows the study selection process. These eligible studies were from all over the world. In all studies, the genotype frequencies in controls were consistent with HWE. There were five studies that did not follow the HWE. 13, 16, 20, 34, 51 The NOS results indicated that the methodological quality was generally good.
Meta-analysis
For the apoB EcoRI polymorphism, significant heterogeneity was found in the allelic model (I 2 = 56%, p<0.0001) and dominant genetic model (I 2 = 68%, p<0.00001). Therefore, the random-effects model (DerSimonian and Kacker) was applied. No significant heterogeneity was found under the recessive genetic model (I 2 = 0, p = 0.95), therefore, the Mantel-Haenszel fixed effects model was used. Significant statistical association was observed between the apoB EcoRI polymorphism and CHD under the allelic contrast (A vs. G, p = 0.001, OR = 1.33, 95% CI = 1.12-1.57) ( Figure 2 ). Both the dominant genetic model (AA+GA vs. GG, p = 0.005, OR = 1.22, 95% CI = 1.06-1.40) and the recessive genetic model (AA vs. GA+GG, p = 0.04, OR = 1.33, 95% CI = 1.01-1.74) were also obtained similar results. For the apoB XbaI polymorphism, significant heterogeneity was found under the allelic contrast (I 2 = 69%, p < 0.00001), dominant genetic model (I 2 = 55%, p <0.0001) and the recessive genetic model (I 2 = 68%, p<0.00001). The random-effects model was applied to perform meta-analysis.
No significant statistical association was found under the allelic contrast (T vs. C, P=0.51, OR = 0.96, 95% CI = 0.84-1.09) ( Figure 3 ), dominant genetic model (TT+TC vs. CC, p = 0.92, OR = 0.99, 95% CI = 0.80-1.23), and recessive genetic model (TT vs. TC+CC, p = 0.86, OR = 1.02, 95% CI = 0.85-1.22). As to the apoB SpIns/Del polymorphism, significant heterogeneity was found under the allelic contrast (I 2 = 84%, p < 0.00001) and dominant genetic model (I 2 = 57%, p = 0.0002). Therefore, the random-effects model was applied. No significant heterogeneity was found under the recessive genetic model (I 2 = 40%, p = 0.02), we utilized the fixed effects model. Significant statistical association was observed between the apoB SpIns/Del polymorphism and CHD under the allelic contrast (D vs. I, p = 0.01, OR = 1.20, 95% CI = 1.04-1.39) ( Figure 4 ), dominant genetic model (DD+DI vs. II, p = 0.004, OR = 1.20, 95% CI = 1.06-1.35), and the recessive genetic model (DD vs. DI+II, p = 0.0002, OR = 1.25, 95% CI = 1.11-1.40). After restricting our analysis to the subgroup of Chinese individuals, apoB XbaI polymorphism was significantly associated with CHD under the allelic contrast (T vs. C, p = 0.0001, OR = 0.46, 95% CI = 0.31-0.68), dominant genetic model (TT+TC vs. CC, p = 0.0002, OR = 0.35, 95% CI = 0.20-0.61), and the recessive genetic model (TT vs. TC+CC, p = 0.0007, OR = 0.48, 95% CI = 0.32-0.73). apoB EcoRI polymorphism and risk of CHD were found under the allelic contrast (A vs. G, p = 0.0006, OR = 1.46, 95% CI = 1.18-1.82) and dominant genetic model (AA+GA vs. GG, P = 0.002, OR = 1.38, 95% CI = 1.13-1.68). However, we did not find any association under the recessive genetic model (AA vs. GA+GG, p = 0.14, OR = 1.88, 95% CI = 0.81-4.36). Furthermore, no significant statistical association was observed between the apoB SpIns/Del polymorphism and CHD under the allelic contrast (D vs. I, p = 0.07, OR = 1.21, 95% CI = 0.98-1.50), dominant genetic model (DD+DI vs. CC, p = 0.09, OR = 1.24, 95% CI = 0.96-1.58) and the recessive genetic model (DD vs. DI+II, p = 0.27, OR = 1.39, 95% CI = 0.77-2.49).
When stratified by status of HWE (the presence or absence of HWE in controls), no significant heterogeneity was found under the allelic contrast, dominant genetic model and recessive genetic model for EcoRI, XbaI, and SpIns/Del polymorphisms. Significant statistical association still existed in the whole group and subgroup of Chinese population.
The contribution of each study to the pooled estimate was performed in order to assess the sensitivity analyses. We excluded individual studies one at a time and recalculated the pooled p or OR for the remaining studies. Huang et al.'s study had an undue influence on the pooled p or OR estimation in SpIns/Del polymorphism. 65 This result showed the reliability of our results. What is more, conversion between the two models also did not substantially change the pooled point estimate.
Publication bias
No obvious publication bias was found in the present study. The publication bias of the individual studies was evaluated using a funnel plot and Egger's test. No visual publication bias was found in the funnel plot for the EcoRI (Figure 5(a) ), XbaI ( Figure 5(b) ), or SpIns/Del ( Figure 5(c) ) gene polymorphisms. We further used Egger's test to assess the whole test publication bias. No statistically significant difference was detected in the Egger's test by using the allelic contrast model for EcoRI (T = 0.29, p = 0.775), XbaI (T = 1.09, p = 0.283), and SpIns/Del (T = 1.43, p = 0.165) polymorphisms in all studies. In the subgroup no statistically significant difference was detected by using the Egger's test.
Discussion
In the present study, we found an association of EcoRI polymorphism with an increased risk of CHD. No significant association between apoB XbaI polymorphism and CHD was observed in all studies. For SpIns/Del polymorphism, an association was observed in all studies. However, no significant statistical association was found in Chinese people. CHD is a multi-factorial and polygenic disorder which is thought to be the result of interactions between complex factors of gene-gene and gene-environment. The association between apoB gene polymorphisms and the risk of CHD has been widely studied, but the results remain inconclusive. For example, Baroni et al. reported a significant difference in the development of CHD between genotype classes of the XbaI polymorphism in an Italian population. 13 Duman et al. did not observe significant differences in the frequencies of apoB XbaI (CC, CT, TT) and EcoRI (AA, AG, GG) genotypes between case and control subjects in Turkish. 20 Gallegos-Arreola et al. detected that the apoB XbaI (CC) genotype is associated with CAD patients in the Mexican population. 21 Kallel et al. found a significant but not independent association between the Ins/Del polymorphism of the apoB gene and MI in the Tunisian population. 31 Marshall et al. found no evidence that the apoB Ins/Del polymorphism had a significant influence on the risk of angiographically defined CAD. 39 In contrast, Hong et al. observed that the Ins allele frequency was significantly higher in patients than in healthy controls in a Korean case control study with 216 controls and 235 CAD patients. 26 In order to generate robust data on apoB gene (EcoRI, XbaI, and SpIns/Del) polymorphisms and CAD risk, we carried out an update meta-analysis involving 54 studies and focusing on worldwide studies to provide the most comprehensive analysis on the relationship between apoB gene polymorphisms and CAD risk. The effects of the dominant model, the recessive genetic model, and allelic contrast were estimated.
This meta-analysis revealed that EcoRI and SpIns/Del polymorphisms of apoB gene significantly increased the susceptibility for CHD. No significant statistical association was observed under XbaI polymorphism. The results were the same as those of a previous meta-analysis performed by Chiodini et al. in 2003. 2 Another meta-analysis was performed by Boekholdt et al. in Caucasians. 3 Subjects homozygous for the rare EcoRI allele had significantly decreased levels of total and LDL cholesterol, but unaltered risk of CHD. Homozygotes for the XbaI C allele had significantly elevated levels of LDL cholesterol (LDL-C) and apoB, but a decreased risk of CHD. Homozygosity for the SpIns/Del D allele was associated with similarly increased levels of LDL-C and apoB, and with an increased risk of CHD. In our meta-analysis, in Chinese individuals, the XbaI polymorphism decreased the risk of CHD. The results were in line with a meta-analysis carried out by Chen et al. in 2006. 4 As to SpIns/Del polymorphism, no significant statistical association was observed.
However, only full text articles published in English and Chinese were included in this meta-analysis, missing some eligible studies which were unpublished or reported in other languages. In this case, some inevitable publication bias might exist, although the funnel plots did not indicate obvious publication bias in the present meta-analysis. It might influence the interpretation of our final results.
For better interpreting the results, some limitations of this meta-analysis should be acknowledged. First, heterogeneity may affect the results of the present meta-analysis in our analysis. Second, subgroup analysis was not performed by the factors such as gender, age and experimental method because insufficient data could be extracted from the primary article. Further studies with large sample size, especially in subgroup analysis of different minority, were needed to confirm our findings.
Despite these limitations or disadvantages, our metaanalysis still had some advantages. First, a systematic review of the association of apoB gene (EcoRI, XbaI, and SpIns/Del) polymorphisms with CHD risk is statistically more powerful than any single study. Second, the studies retrieved were the latest; many of them were published after the previous meta-analysis. Third, the quality of case-control studies included in our meta-analysis was satisfactory and met our inclusion criteria.
Conclusions
In summary, the present meta-analysis points to an association of EcoRI polymorphism with an increased risk of CHD. No significant association between apoB XbaI polymorphism and CHD we observed in all studies, but it is a reduced risk of CHD in Chinese people. For SpIns/ Del polymorphism, an association was observed in all studies. However, no significant statistical association was found under Chinese individuals. On the other hand, Huang and Xie found that combined polymorphisms of apoB and APOAI gene are related with CHD. 28 Scartezini et al. observed that individuals with the TT/GG genotype presented a 6.1 higher chance of developing CHD than individuals with the other XbaI/EcoRI genotypes in Brazilian patients. 52 We conclude that the TT/GG genotype may be in linkage disequilibrium with an unknown variation in the apoB gene or with a variation in another gene that affects the risk of CHD. Larger scale primary studies with the consideration of gene-gene and geneenvironment interactions are still required to further evaluate the interaction of apoB gene polymorphisms with CHD susceptibility. 
